|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.003 AUD | -25.00% |
|
-14.29% | -14.29% |
| 16/05 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
| 25/03 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Avecho Biotechnology Limited reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was AUD 0.7936 million compared to AUD 0.384627 million a year ago. Net loss was AUD 3.42 million compared to AUD 2.63 million a year ago.
Basic loss per share from continuing operations was AUD 0.0019 compared to AUD 0.0017 a year ago. Diluted loss per share from continuing operations was AUD 0.0019 compared to AUD 0.0017 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.29% | 63.29L | |
| +54.05% | 6.39TCr | |
| -2.02% | 4.18TCr | |
| +40.01% | 4.05TCr | |
| -10.22% | 2.72TCr | |
| +13.42% | 2.65TCr | |
| -21.60% | 1.87TCr | |
| +2.89% | 1.27TCr | |
| +22.40% | 1.21TCr | |
| +27.49% | 1.21TCr |
AVECHO BIOTECHNOLOGY LIMITED 
